Kevin Hourican
CIK 1741853 · View on SEC EDGAR ↗
First SEC filing: June 8, 2018 · Latest: Sept. 4, 2025
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Oct. 24, 2022 | SYY | S 10b5-1 | 75,019 | $81.22 | $6,093,043 | 303,643 Direct | -19.81% | Disposed | 3.5% (price as of 2026-08-21) |
| April 8, 2022 | SYY | S 10b5-1 | 75,018 | $86.00 | $6,451,548 | 88,477 Direct | -45.88% | Disposed | -2.2% (price as of 2026-08-21) |
| Aug. 27, 2018 | CVS | S 10b5-1 | 8,564 | $75.00 | $642,300 | 3,571 Direct | -70.57% | Disposed | 24.8% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Aug. 21, 2025 | SYY | Stock Options (Right to buy) | Common Stock (128,039) | $80.98 | Aug. 20, 2035 | 128,039 | Acquired |
| Aug. 21, 2024 | SYY | Stock Options (Right to buy) | Common Stock (130,140) | $76.54 | Aug. 20, 2034 | 130,140 | Acquired |
| Feb. 29, 2024 | TPR | Stock Option [F2] | Common Stock (5,280) | $47.53 | March 1, 2034 | 5,280 | Acquired |
| Aug. 10, 2023 | SYY | Stock Options (Right to buy) | Common Stock (124,869) | $74.85 | — | 124,869 | Acquired |
| Oct. 24, 2022 | SYY | Stock Options (Right to buy) | Common Stock (75,019) | $58.08 | Aug. 19, 2030 | 75,019 | Disposed |
| Aug. 18, 2022 | SYY | Common Stock | Common Stock (136,363) | $85.57 | Aug. 17, 2032 | 136,363 | Acquired |
| April 8, 2022 | SYY | Stock Options (Right to buy) | Common Stock (75,018) | $58.08 | Aug. 19, 2030 | 75,018 | Disposed |
| Aug. 19, 2021 | SYY | Stock Options (Right to buy) | Common Stock (181,268) | $76.94 | Aug. 18, 2031 | 181,268 | Acquired |
| Aug. 20, 2020 | SYY | Stock Options (Right to buy) | Common Stock (225,056) | $58.08 | Aug. 19, 2030 | 225,056 | Acquired |
| Feb. 12, 2020 | SYY | Stock Options (Right to buy) | Common Stock (683,303) | $76.27 | Feb. 11, 2030 | 683,303 | Acquired |
| April 1, 2019 | CVS | Stock Option | Common Stock (202,007) | — | April 1, 2029 | 202,007 | Acquired |
| Aug. 27, 2018 | CVS | Stock Option | Common Stock (4,426) | $54.53 | April 1, 2020 | 4,426 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 13 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| June 8, 2018 | CVS | Common Stock | 7,709 | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | — | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | — | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | — | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | — | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | — | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | — | Direct |
| June 8, 2018 | CVS | Stock Option→ Common Stock (4,426) | 4,426 | Direct |
| June 8, 2018 | CVS | Stock Option→ Common Stock (9,442) | 9,442 | Direct |
| June 8, 2018 | CVS | Stock Option→ Common Stock (17,822) | 17,822 | Direct |
| June 8, 2018 | CVS | Stock Option→ Common Stock (17,611) | 17,611 | Direct |
| June 8, 2018 | CVS | Stock Option→ Common Stock (30,169) | 30,169 | Direct |
| June 8, 2018 | CVS | Stock Option→ Common Stock (87,575) | 87,575 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
SYY
CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $1,296,438 | — | $7,775,318 | $3,299,985 | $1,762,976 | — | $206,303 | $14,341,020 |
| 2022 | $1,296,438 | — | $6,990,845 | $3,146,812 | $2,070,900 | — | $151,511 | $13,656,506 |
| 2021 | $1,350,000 | — | $16,130,478 | $3,024,753 | $2,272,725 | — | $419,168 | $23,197,124 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.